Evaluating the Safety and Immune Response to a Single Dose of a Respiratory Syncytial Virus (RSV) Vaccine in Infants and Children
Completed · Phase 1 · Has a placebo group
Conditions studied: Respiratory Syncytial Virus Infections
In brief
Human respiratory syncytial virus (RSV) is a common cause of respiratory illness in infants and children around the world. This study will evaluate the safety and immune response to a RSV vaccine in three groups of participants: healthy children who have already had an RSV infection (RSV seropositive), healthy infants and children who have not already had an RSV infection (RSV seronegative), and healthy younger infants who have not been screened for prior RSV infection.
Key facts
- Study ID
- NCT01893554
- Run by
- National Institute of Allergy and Infectious Diseases (NIAID)
- People needed
- 88
- Starts
- 2013-06-01
- Expected to finish
- 2023-04-26
- Last updated by the study team
- 2026-05-13
Who can join
Age: 0 and older, up to 5. Sex: any. Healthy volunteers: accepted.
Where it is running
- Center for Immunization Research (CIR) — Baltimore, Maryland, United States
- Center for Immunization Research South — Laurel, Maryland, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.